This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Promus PREMIER™ Everolimus-Eluting Platinum Chromium Stent System Receives CE Mark Approval

NATICK, Mass., Feb. 12, 2013 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) has received CE Mark approval for the Promus PREMIER™ Everolimus-Eluting Platinum Chromium Coronary Stent System, the company's next-generation durable polymer drug-eluting stent (DES) technology, and is starting its European market launch.  The Promus PREMIER Stent System is designed to provide physicians improved DES performance in treating patients with coronary artery disease.  It is the only platform to feature a customized Platinum Chromium (PtCr) stent architecture, the market-leading Everolimus drug coating and fluorinated co-polymer, and an enhanced stent delivery system.  Images of the Promus PREMIER Stent System are available for download here.

Coronary heart disease is a narrowing of the vessels that supply blood and oxygen to the heart.  Recent statistics from the European Heart Network and the European Society of Cardiology show it is the single most common cause of death in Europe accounting for 1.8 million deaths in Europe per year.  Patients living with coronary heart disease, also known as coronary artery disease, may experience pain, shortness of breath and fatigue.  They may also be at risk for a heart attack.  One treatment option is the placement of a stent in the artery to help keep it open and allow the blood to flow more freely.   

"The customized Platinum Chromium stent architecture maintains the superior visibility, exceptional radial strength and fracture resistance, minimal recoil and outstanding clinical outcomes of a PtCr Everolimus-Eluting stent while offering improved longitudinal strength," said John Ormiston, M.D., Mercy Angiography, Auckland City, New Zealand.   "In addition, the enhanced stent delivery system offers improved deliverability.  Stent design is a balance of trade-offs and the Promus PREMIER Stent System appears to have it right."

The Promus PREMIER Stent System was developed with input from physicians.  The customized Platinum Chromium alloy stent architecture provides strength without compromising flexibility.  An enhanced low-profile delivery system features a shorter, more visible tip, dual-layer balloon and Bi-Segment™ inner lumen catheter designed to facilitate precise stent delivery across challenging lesions. The Everolimus drug and fluorinated co-polymer stent coating have been studied in multiple randomized clinical trials demonstrating long-term safety and efficacy.  The PLATINUM Workhorse Trial compared the PROMUS Element™ Stent (Platinum Chromium Everolimus-Eluting stent) to the Xience V™ Stent (Cobalt Chromium Everolimus-Eluting stent), and demonstrated that Platinum Chromium technology has superior clinical outcomes between years one and two.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 16,472.37 +200.36 1.23%
S&P 500 1,951.36 +27.54 1.43%
NASDAQ 4,707.7750 +80.6910 1.74%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs